Amgen Reports Second Quarter 2017 Financial Results

THOUSAND OAKS, Calif., July 25, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2017. Key results include:

Total revenues increased 2 percent versus the second quarter of 2016 to $5.8 billion.

Product sales grew 2 percent driven by Prolia® (denosumab), Repatha® (evolocumab) and KYPROLIS® (carfilzomib).

GAAP earnings per share (EPS) increased 18 percent to $2.91 driven by higher operating margins.

GAAP operating income increased 13 percent to $2.7 billion and GAAP operating margin increased 4.9 percentage points to 48.4 percent.

Non-GAAP EPS increased 15 percent to $3.27 driven by higher operating margin...

Source: Amgen News Release - July 25, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news